Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

Biotecnología

Mr. Jonathan  Schwartz M.D.

Chief Gene Therapy Officer & Senior Vice President of Clinical Devel.

Mr. Jonathan  Schwartz

Chief Medical Officer & Senior Vice President of Clinical Devel.

Ms. Jessie  Yeung M.B.A.

Vice President of Investor Relations & Corporation Fin.

Kevin  Giordano

Director of Corporation Communications

Mr. John C. Militello CPA, CPA

Vice President, Senior Controller, Treasurer, Principal Accounting Officer & Interim Principal Financial Officer

Mr. Raj  Prabhakar M.B.A.

Senior Vice President & Chief Bus. Officer

Mr. Martin Louis Wilson J.D.

Gen. Counsel, Chief Compliance Officer & Senior Vice President

Ms. Isabel  Carmona J.D.

Senior Vice President & Chief HR Officer

Dr. Gayatri R. Rao J.D., M.D.

Chief Devel. Officer of LVV & Senior Vice President

Mayur  Kasetty M.B.A., M.D.

Bus. Devel. & Operations and Investor Relations Lead

Mr. Mayo  Pujols

Chief Technical Officer, Executive Vice President & Director

Interim Principal Financial Officer, Vice President, Senior Controller, Treasurer & Principal Accounting Officer

Nombre	Capitalización
hVIVO plc	0M
VistaGen Therapeutics, Inc.	0M
BioVaxys Technology Corp.	0M
MedMira Inc.	0M
Regenicin, Inc.	0M
Vascular Biogenics Ltd.	0M
CorMedix Inc.	0M
Wave Life Sciences Ltd.	0M
Immuron Limited	0M
Aptevo Therapeutics Inc.	0M

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. Lista de competidores

Principales competidores